Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric Inotuzumab Ozogamicin for relapsed/refractory CD22-positive B-cell malignancies
NL-OMON47372Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and 3 more (3 arms), sponsored by Erasmus MC. Primary endpoints: Dose-limiting toxicities, Overall response rate and 1 more. Started Jan 2017; status: recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)Burkitt lymphoma (BL)Burkitt leukemia
Beyond the preview
Go deeper on NL-OMON47372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47372.